While many studies have demonstrated overexpression of YB-1 in different cancer types, only a fraction of those have looked at the presence of the S102 phosphorylated form and ours is the first to demonstrate S102 phosphorylated YB-1 in cell lines and histological sections of PM, which still lacks druggable targets for therapeutic interventions. This evidence concerns the gene YBX1 and cancer.